Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8903319 | 1.00 | TDP1 (0.33) | TDP1ALDH1A1CYP2A6ALOX12MEN1 | |
| SCHEMBL8023274 | 0.83 | — | — | |
| SCHEMBL21647857 | 0.83 | — | — | |
| SCHEMBL21647884 | 0.62 | — | — | |
| SCHEMBL21462873 | 0.62 | — | — | |
| SCHEMBL868008 | 0.62 | CYP19A1 (0.41) | ALDH1A1MEN1LMNATHRBBLM | |
| SCHEMBL19871625 | 0.61 | CYP3A4 (0.35) | TDP1ALDH1A1CYP2A6ALOX12MEN1 | |
| SCHEMBL5084226 | 0.61 | CYP2A6 (0.31) | TDP1CYP2A6ALOX12MEN1LMNA | |
| SCHEMBL18387086 | 0.61 | TSHR (0.35) | TDP1CYP2A6ALOX12MEN1LMNA | |
| SCHEMBL134062 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108548-A1 | MOLECULAR TWEEZERS FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108548-A1 | MOLECULAR TWEEZERS FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | TDP1 659/4885ALDH1A1 4661/4885CYP2A6 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.